(RTTNews) - Biogen Inc. (BIIB) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European Medicines ...
Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational drug-device combination to treat certain patients with non-muscle invasive ...
Elicio Therapeutics received FDA feedback supporting ELI-002's Phase 3 study design; Phase 2 analysis results expected in H1 2025. Elicio Therapeutics announced positive feedback from the FDA ...
(RTTNews) - Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in ...
(RTTNews) - AstraZeneca (AZN), on Friday, announced that the FDA has approved CALQUENCE in combination with bendamustine and rituximab for the first-line treatment of adult patients with ...
FDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast Cancer
(RTTNews) - The U.S. Food and Drug Administration approved AstraZeneca (AZN, AZN.L) and Daiichi Sankyo's (DSKYF.PK) Datroway (datopotamab deruxtecan-dlnk) for the treatment of adult patients with ...
BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's
The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds. Rising interest rates, challenges in the U.S. healthcare system, and the inherent risks of drug development have contributed to the sector's underperformance relative to the broader markets during this period.
Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward tech innovation.
Celularity Inc., a biotechnology firm specializing in pharmaceutical preparations, has terminated a significant agreement with an institutional investor as of Wednesday. The deal, initially disclosed on January 3,
Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases, with its lead candidate nomlabofusp targeting Friedreich's ataxia (FA).
There are lots of interesting companies that make Bedford their home. Here is a quick recap of what’s happening around town with some businesses in the community in January.
Feedback